Shares of GlaxoSmithKline (NYSE:GSK) have earned a consensus rating of “Hold” from the seventeen analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $42.00.
Several brokerages have recently commented on GSK. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating and set a $46.00 price objective on the stock. in a research report on Wednesday, April 11th. Deutsche Bank restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, April 9th. BNP Paribas upgraded shares of GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a research report on Wednesday, April 4th. Finally, Morgan Stanley upgraded shares of GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a research report on Thursday, March 22nd.
GSK opened at $40.51 on Friday. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60. GlaxoSmithKline has a 1-year low of $34.52 and a 1-year high of $44.53. The company has a market capitalization of $100,342.70, a price-to-earnings ratio of 14.00, a price-to-earnings-growth ratio of 2.13 and a beta of 0.84.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The business had revenue of $10.14 billion for the quarter, compared to the consensus estimate of $9.89 billion. equities analysts anticipate that GlaxoSmithKline will post 2.94 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd were given a dividend of $0.633 per share. This represents a $2.53 annualized dividend and a dividend yield of 6.25%. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend was Thursday, February 22nd. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 89.93%.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Field & Main Bank bought a new stake in GlaxoSmithKline in the 4th quarter valued at $132,000. Amussen Hunsaker Associates LLC bought a new stake in GlaxoSmithKline in the 4th quarter valued at $141,000. First Dallas Securities Inc. bought a new stake in GlaxoSmithKline in the 4th quarter valued at $142,000. Belpointe Asset Management LLC bought a new stake in GlaxoSmithKline in the 3rd quarter valued at $204,000. Finally, California Capital Advisors Inc. bought a new stake in GlaxoSmithKline in the 4th quarter valued at $210,000. Institutional investors own 10.96% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline (GSK) Receives $42.00 Consensus Price Target from Analysts” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/18/glaxosmithkline-gsk-receives-42-00-consensus-price-target-from-analysts.html.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.